|Pronunciation||a" va trom' boe pag|
|Other names||Avatrombopag maleate|
|Drug class||Thrombopoietin receptor agonist|
|Main uses||Low platelets in chronic liver disease|
|Side effects||Fever, abdominal pain, nausea, headache, tiredness, peripheral swelling|
|Typical dose||40 to 60 mg OD|
|Chemical and physical data|
|Molar mass||649.65 g·mol−1|
|3D model (JSmol)|
Common side effects include fever, abdominal pain, nausea, headache, tiredness, and peripheral swelling. Other side effects may include blood clots. Use in pregnancy may harm the baby. Safety in pregnancy or breastfeeding is unclear. It is a thrombopoietin receptor agonist, which increases platelet production.
Avatrombopag was approved for medical use in the United States in 2018 and Europe in 2019. In the United Kingdom a course of treatment costs the NHS £640 to £960 as of 2020. In the United States this amount is 3,650 USD to 5,500 USD.
- BNF 81: March-September 2021. BMJ Group and the Pharmaceutical Press. 2021. p. 1079. ISBN 978-0857114105.
- "Avatrombopag Monograph for Professionals". Drugs.com. Archived from the original on 25 January 2021. Retrieved 16 January 2022.
- "Doptelet EPAR". European Medicines Agency (EMA). 24 April 2019. Archived from the original on 22 May 2020. Retrieved 2 May 2020.
- "Avatrombopag for treating thrombocytopenia in people with chronic liver disease needing a planned invasive procedure". Archived from the original on 17 January 2022. Retrieved 16 January 2022.
- "Doptelet Prices, Coupons & Patient Assistance Programs". Drugs.com. Archived from the original on 16 April 2021. Retrieved 16 January 2022.